Eli Lilly and Co (MIC:LLY-RM) Cyclically Adjusted PS Ratio: (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co  (MIC:LLY-RM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.14 13.57 20.20 23.93 28.40

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.64 22.34 20.92 28.40 22.92

MIC:LLY-RM vs JNJ, ABBV, MRK: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1796.452/330.2130*330.2130
=1,796.452

Current CPI (Mar. 2026) = 330.2130.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 325.354 241.018 445.760
201609 308.722 241.428 422.254
201612 326.688 241.432 446.820
201703 277.102 243.801 375.317
201706 327.386 244.955 441.335
201709 310.171 246.819 414.970
201712 179.995 246.524 241.099
201803 270.717 249.554 358.216
201806 340.640 251.989 446.384
201809 338.880 252.439 443.286
201812 383.771 251.233 504.417
201903 335.903 254.202 436.344
201906 384.421 256.143 495.586
201909 375.983 256.759 483.545
201912 413.846 256.974 531.794
202003 511.546 258.115 654.434
202006 422.450 257.797 541.118
202009 497.374 260.280 631.010
202012 606.400 260.474 768.757
202103 566.169 264.877 705.823
202106 544.183 271.696 661.387
202109 543.370 274.310 654.106
202112 638.910 278.802 756.725
202203 904.505 287.504 1,038.870
202206 452.673 296.311 504.465
202209 463.109 296.808 515.231
202212 493.792 296.797 549.387
202303 579.741 301.836 634.245
202306 747.315 305.109 808.803
202309 1,017.896 307.789 1,092.055
202312 933.674 306.746 1,005.103
202403 887.675 312.332 938.494
202406 1,130.030 314.175 1,187.716
202409 1,145.490 315.301 1,199.665
202412 1,612.240 315.605 1,686.864
202503 1,167.740 319.799 1,205.767
202506 1,343.924 322.561 1,375.805
202509 1,626.712 324.800 1,653.822
202512 1,707.650 324.054 1,740.106
202603 1,796.452 330.213 1,796.452

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.